BlueCrest Capital Management
WGS icon

BlueCrest Capital Management’s GeneDx Holdings WGS Stock Holding History

BlueCrest Capital Management’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,736
Closed -$3.8M – 551
2021
Q1 		$3.8M Buy
+7,736
New +$4.02M 0.06% 375

Other funds holding WGS

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Weiss Multi-Strategy Advisers
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Third Point
Third Point New York $4.68B AUM 37.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Jefferies Group
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlueCrest Capital Management's WGS Position: Q2 2021 in Review

BlueCrest Capital Management sold out of GeneDx Holdings (WGS) in Q2 2021, closing a stake of 7,736 shares — an estimated $3.8M sold.

BlueCrest Capital Management first reported a position in WGS in Q1 2021 and held it in 1 quarter. The position peaked at $3.8M in Q1 2021. 67 funds tracked by Wall St. Rank hold WGS as of Q2 2021.

  • BlueCrest Capital Management reported no remaining GeneDx Holdings position as of Q2 2021 after selling out during the quarter.
  • BlueCrest Capital Management sold 7,736 GeneDx Holdings shares in Q2 2021, an estimated $3.8M.
  • BlueCrest Capital Management first reported a position in GeneDx Holdings in Q1 2021 and held it in 1 quarter.
  • BlueCrest Capital Management's GeneDx Holdings position peaked at $3.8M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2021.

Based on BlueCrest Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.